The Chinse drug administration approved Chongqing Lummy Pharmaceutical's (SHE:300006) supplementary application for alanyl glutamine injection's two specifications, according to a Shenzhen Stock Exchange disclosure on Tuesday.

The approval covers 50 milliliters: 10 grams and 100ml:20g.

The drug is suitable for parenteral nutrition of patients who need glutamine supplementation, including those with catabolic and hypermetabolic conditions, the pharmaceutical company said.

Lummy's shares jumped more than 8% in recent trade.